Novo is aggressively restocking its cardiometabolic pipeline. The Danish pharma announced a biobucks deal worth up to $1.4 billion with Orbis Medicines, a Danish startup specializing in oral macrocycles—large ring-shaped molecules that could offer an alternative to injected peptides. The collaboration will target cardiometabolic conditions, according to Fierce Biotech and BioPharma Dive.
In a separate move, Novo purchased three early-stage obesity drug programs from Kallyope, a New York biotech. These programs are described as early-stage, and the financial terms were not disclosed in the source reports. Together, the two deals signal a broader strategy: doubling down on oral, convenient therapies rather than relying solely on injectable GLP-1 drugs.
The sources agree on the Orbis deal's headline value and focus, but they differ in framing. Fierce Biotech emphasizes Novo's "rebranded" identity and portfolio rejuvenation, while BioPharma Dive highlights the deepening of oral peptide research. Neither source connects the Kallyope acquisition to the Orbis pact directly, but both point to the same underlying urgency: Novo needs new options as its blockbuster obesity franchise faces competition and patent cliffs. The Kallyope and Orbis programs are at different stages and use different chemistries, so they are complementary rather than overlapping bets.